Exclusion criteria:
|
(1) Select patients who have taken drugs or acupuncture treatment for benign prostatic hyperplasia within the first month;
(2) Combined with other diseases that can lead to micturition symptoms or changes in urinary flow rate, such as neurogenic bladder, bladder neck fibrosis, bladder urinary calculi, urethral stricture, phimosis or penile tumor, acute prostatitis, prostate cancer, acute and chronic urinary tract infection, acute and chronic renal failure, etc;
(3) Previous prostate surgery, including transurethral resection of the prostate, transurethral enucleation of the prostate, transrectal high-intensity focused ultrasound, transurethral needle ablation, balloon dilatation, stent replacement, or other invasive treatment of benign prostatic hyperplasia;
(4) Patients who plan to undergo minimally invasive treatment or surgical treatment of prostate;
(5) Patients with long-term use of drugs that affect bladder function: α- Adrenoceptor agonists (such as norepinephrine, pseudoephedrine, deoxyepinephrine); Cholinergic drugs (neostigmine); Anticholinergic drugs (such as atropine, scopolamine, anisodamine, etc.) or other drugs that affect urination function;
(6) Patients whose ALT and AST are 1.5 times higher than the upper limit of normal value, or whose Cr is higher than the upper limit of normal value;
(7) Patients with other serious cardiovascular, cerebrovascular, liver, kidney, malignant tumors, hematological diseases, and mental diseases;
(8) Those who are allergic to the ingredients of the test drug or have a history of drug abuse;
(9) Patients who participated in other clinical trials within 3 months before screening;
(10) The investigator judged the patients who were not suitable to participate in this trial.
|